학술논문
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial
Document Type
Article
Author
Lobo, S.M.; Plantefève, G.; Nair, G.; Joaquim Cavalcante, A.; Franzin de Moraes, N.; Nunes, E.; Barnum, O.; Berdun Stadnik, C.M.; Lima, M.P.; Lins, M.; Hajjar, L.A.; Lipinski, C.; Islam, S.; Ramos, F.; Simon, T.; Martinot, J.-B.; Guimard, T.; Desclaux, A.; Lioger, B.; Neuenschwander, F.C.; DeSouza Paolino, B.; Amin, A.; Acosta, S.A.; Dilling, D.F.; Cartagena, E.; Snyder, B.; Devaud, E.; Barreto Berselli Marinho, A.K.; Tanni, S.; Milhomem Beato, P.M.; De Wit, S.; Selvan, V.; Gray, J.; Fernandez, R.; Pourcher, V.; Maddox, L.; Kay, R.; Azbekyan, A.; Chabane, M.; Tourette, C.; Esmeraldino, L.E.; Dilda, P.J.; Lafont, R.; Mariani, J.; Camelo, S.; Rabut, S.; Agus, S.; Veillet, S.; Dioh, W.; van Maanen, R.; Morelot-Panzini, C.
Source
In: eClinicalMedicine . (eClinicalMedicine, February 2024, 68)
Subject
Language
English
ISSN
25895370